Portfolio Design Labs LLC Boosts Stock Position in Johnson & Johnson (NYSE:JNJ)

Portfolio Design Labs LLC grew its stake in Johnson & Johnson (NYSE:JNJ) by 35.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 18,318 shares of the company’s stock after purchasing an additional 4,774 shares during the period. Portfolio Design Labs LLC’s holdings in Johnson & Johnson were worth $2,649,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. IFS Advisors LLC grew its holdings in Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after acquiring an additional 100 shares during the period. Highline Wealth Partners LLC acquired a new position in shares of Johnson & Johnson during the 3rd quarter worth $31,000. Bay Harbor Wealth Management LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at about $32,000. RPg Family Wealth Advisory LLC acquired a new stake in shares of Johnson & Johnson in the third quarter valued at about $35,000. Finally, Mowery & Schoenfeld Wealth Management LLC boosted its holdings in Johnson & Johnson by 58.7% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock worth $40,000 after buying an additional 91 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $156.20 on Friday. The business’s 50-day simple moving average is $147.73 and its 200-day simple moving average is $156.01. The firm has a market capitalization of $376.08 billion, a P/E ratio of 23.49, a P/E/G ratio of 2.46 and a beta of 0.52. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. Johnson & Johnson’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the previous year, the firm earned $2.29 earnings per share. Equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.18%. Johnson & Johnson’s payout ratio is currently 74.59%.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Morgan Stanley cut their price target on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Bank of America dropped their price objective on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research note on Thursday, January 23rd. Argus raised Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Wolfe Research assumed coverage on Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 price target for the company. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a research note on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $170.67.

Insider Buying and Selling

In other news, Director Mark A. Weinberger bought 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.